EDAP TMS (EDAP) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
EDAP TMS S.A., a company specializing in robotic High-Intensity Focused Ultrasound (HIFU) technologies for prostate cancer, reported significant growth in 2023 with record revenues, increased adoption of its Focal One systems, and significant clinical and regulatory milestones. Notably, the company received a positive opinion from the French National Authority for Health and reimbursement approval in Switzerland for HIFU prostate cancer treatments. Looking ahead, EDAP anticipates a strong pipeline for Focal One, despite a modest elongation in purchasing cycles due to economic conditions, and appeals to shareholders to support upcoming resolutions in their General Meeting.
For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.